New hope for relapsed myeloma: Triple-Drug cocktail under study
NCT ID NCT02244125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs—pomalidomide, cyclophosphamide, and dexamethasone—in 100 patients with multiple myeloma that had returned after initial treatment. All patients had previously been part of the IFM/DFCI 2009 trial. The goal was to see how many patients responded after four cycles of treatment. The study is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pomalidomide, cyclophosphamide, and dexamethasone
What this could lead to
If successful, this combination could offer a new treatment option for multiple myeloma patients whose cancer has returned after initial therapy.
What could go wrong
This is a phase 2 trial with only 100 patients, so results may not apply to everyone. Side effects from the drugs can be serious, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU - Hôpital Claude Huriez
Lille, 59037, France
-
CHRU Dijon
Dijon, 21000, France
-
CHRU Hopital Bretonneau
Tours, 37044, France
-
CHRU Hopital Pontchaillou
Rennes, 35033, France
-
CHRU Hopital Saint Antoine
Paris, 75012, France
-
CHRU Hopital Sud
Amiens, 80054, France
-
CHRU Hopitaux de Brabois
Vandœuvre-lès-Nancy, 54511, France
-
CHRU Hôpital Haut Lévêque
Pessac, 33604, France
-
CHU Carémeau
Nîmes, 30029, France
-
CHU Henri Mondor
Créteil, 94010, France
-
CHU de Limoges
Limoges, 87042, France
-
CHU de Nantes
Nantes, 44093, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier Annecy Genevois
Pringy, 74374, France
-
Centre Hospitalier Général
Dunkirk, 59385, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Yves Le Foll
Saint-Brieuc, 22027, France
-
Centre Hospitalier de la côte Basque
Bayonne, 64109, France
-
Centre Hospitalier départemental de Vendée
La Roche-sur-Yon, 85925, France
-
Centre René Huguenin
Saint-Cloud, 92210, France
-
Chru Grenoble
Grenoble, 38043, France
-
Chu Estaing
Clermont-Ferrand, 63003, France
-
Clinique Victor Hugo
Le Mans, 72000, France
-
Hopital Emile Muller
Mulhouse, 68100, France
-
Hôpital Avicenne
Bobigny, 93009, France
-
ICH - Hôpital A. Morvan
Brest, 29609, France
-
Institut Curie
Paris, 750005, France
-
Institut Paoli Calmette
Marseille, 13273, France
-
Institut Universitaire du Cancer Toulouse-Oncopôle (IUCT-O)
Toulouse, 31059, France
-
Institut d'Hématologie de Basse Normandie - IHBN
Caen, 14033, France